Sulodexide

DB06271ApprovedInvestigationalWithdrawnProtein Based Therapies

Sulodexide is a drug used to treat chronic venous ulcers in the legs. Sulodexide is a mixture of glycosaminoglycans (GAGs) composed of dermatan sulfate (DS) and fast moving heparin (FMH).

Mechanism
Curator reviewed
Primary indication
Sulodexide has been used clinically for the prophylaxis and treatment of vascular diseases with increased risk of thrombosis, including intermittent claudication, peripheral arterial occlusive disease and post-myocardial infarc-tion.Curator reviewed · 2 structured indications
Formula / weight
6500.0 Da (range 5000-8000)
Code names
KRX-101

Resolves to

Compound
UNII75HGV0062CCAS57821-29-1ChEMBLCHEMBL2108086KEGGD08547
Clinical / RWD
ATCB01AB11PharmGKBPA164746343
Targets
P05546SERPIND1P01008SERPINC1

What you can answer from here — as of March 06, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
866Drug interactionsStructured to mechanism, not free text
Sign in
30Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
3ContraindicationsEach with its own population and attribute set
Sign in
17Marketed productsAcross 4 countries and 8 labellers
Sign in
1ATC codeIncluding every combination product, plus 11 drug categories
Sign in
8+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Sulodexide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In